Akari Therapeutics Plc - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Akari Therapeutics Plc on September 7, 2017, reporting events that occurred on September 1, 2017. The filing details the grant of stock options to specific officers and directors under the Company's Amended and Restated 2014 Equity Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on equity compensation grants and does not contain financial performance data.
Material Changes
The primary material event reported is the grant of stock options to four key individuals:
- David Horn Solomon: 26,000,000 Ordinary Shares (260,000 ADSs)
- Clive Richardson: 4,500,000 Ordinary Shares (45,000 ADSs)
- Robert M. Shaw: 1,800,000 Ordinary Shares (18,000 ADSs)
- Dov Elefant: 500,000 Ordinary Shares (5,000 ADSs)
These options have a ten-year term, an exercise price equal to the closing price on the grant date, and vest ratably over four years beginning on the first anniversary of the grant.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the standard terms of the equity grants.
Investor Verification Points
- Verify the closing share price on September 1, 2017, to determine the exercise price of the granted options.
- Review the Company's 20-F or 10-K filings for the total outstanding share count to assess the dilution impact of these grants.
- Confirm the vesting schedule details in the full text of the Amended and Restated 2014 Equity Incentive Plan.